Celltrion Approvals Set Up Denosumab Showdown In US
Korean Firm Wins FDA Nod For Third Prolia And Xgeva Biosimilars
Celltrion has become the third firm to win FDA approval for US biosimilar rivals to Prolia and Xgeva. But with multiple denosumab competitors set to launch in just a couple of months, and several more candidates on the way, the market looks likely to be another competitive one for biosimilar sponsors.
